This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Markets Rebound Nicely Ahead of Q3 Earnings Season
by Mark Vickery
Even though we've seen more than a dozen companies already officially report Q3 earnings results this period, Q3 earnings season really kicks off with the release of earnings from some of the biggest banks on Wall Street.
Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal
by Zacks Equity Research
PTGX shares jump 30% after reports that J&J is in talks to acquire the biotech firm amid ongoing negotiations.
Is J&J's MedTech Segment Set for Another Quarter of Growth?
by Kinjel Shah
J&J's MedTech sales are gaining traction in Cardiovascular, Surgery, and Vision, even as China???s VBP program continues to weigh on growth.
3 Defensive Stocks to Watch as Trade Tensions Resurface: GILD, JNJ, KR
by Shaun Pruitt
With investors on edge as the world's two largest economies go head-to-head again, seeking out stocks that can offer defensive safety in the portfolio may be necessary
Buying J&J Stock Ahead of Q3 Earnings? Here's What You Should Know
by Kinjel Shah
J&J gears up for Q3 results with solid gains from Darzalex, Tremfya and MedTech, even as Stelara faces fierce biosimilar pressure.
Big Banks Gear Up to Report Q3 Earnings
by Zacks Equity Research
Big Banks Gear Up to Report Q3 Earnings
Pre-markets Up Slightly to Start Friday Trading
by Mark Vickery
We're devoid of major market catalysts until Q3 earnings season builds next week, when the Big Banks begin reporting on Tuesday morning.
BAYRY Begins Phase I Study With KQB548 in KRAS-Mutated Cancers
by Zacks Equity Research
Bayer and Kumquat launch a phase I study of KQB548, aiming to target various KRAS G12D-mutated tumors like pancreatic, colorectal and lung cancer.
BDTX Stock Hits 52 Week High: Is There More Room for Growth?
by Ekta Bagri
Black Diamonds shares surge 86.4% in 2025 as strong silevertinib data and rising estimates fuel optimism for further gains.
Wall Street's Insights Into Key Metrics Ahead of Johnson & Johnson (JNJ) Q3 Earnings
by Zacks Equity Research
Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Why Johnson & Johnson (JNJ) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Bayer Reports Positive Data on Cell Therapy for Parkinson's Disease
by Zacks Equity Research
BAYRY's subsidiary BlueRock reports 36-month data showing its Parkinson's therapy bemdaneprocel remains safe and effective in easing motor symptoms.
Can Elektrofi Acquisition Drive Halozyme's Long-Term Growth?
by Zacks Equity Research
HALO's impending acquisition of Elektrofi will add Hypercon tech to broaden its drug delivery platform and support long-term growth.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump Deal
by Kinjel Shah
Pfizer's landmark pricing deal with Trump sparks a pharma rally as J&J, Bayer and Novartis emerge as strong contenders for inclusion in one's portfolio.
The Zacks Analyst Blog Highlights Microsoft, Amazon.com, Johnson & Johnson and Willis Lease Finance
by Zacks Equity Research
Zacks Analyst Blog highlights Microsoft, Amazon, Johnson & Johnson, and Willis Lease Finance as analysts weigh AI growth, pharma resilience, and niche leasing strength.
Top Analyst Reports for Microsoft, Amazon.com & Johnson & Johnson
by Mark Vickery
Microsoft rides AI and cloud growth, Amazon leans on AWS and Prime, and Johnson & Johnson gains from strong pharma momentum despite patent risks.
How J&J's Innovative Medicines Segment is Poised Ahead of Q3 Results
by Kinjel Shah
JNJ's Innovative Medicine sales face biosimilar pressure and IRA headwinds, but growth drivers like Darzalex, Tremfya and Erleada may have ensured steady Q3 momentum.
Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus
by Santanu Roy
Amneal Pharmaceuticals, Leidos and Vishay Precision stand out as Zacks highlights amid market volatility and shifting rate expectations.
Johnson & Johnson (JNJ) Rises Higher Than Market: Key Facts
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $188.64, moving +1.43% from the previous trading session.
ISRG Expands SP Indications: A Game Changer in Colorectal Surgery?
by Indrajit Bandyopadhyay
Intuitive Surgical's SP platform secures new colorectal clearances, with 88% growth in procedures and rising global adoption momentum.
Johnson & Johnson (JNJ) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
Johnson & Johnson (JNJ) closed at $179.71 in the latest trading session, marking a +1.11% move from the prior day.
Has AbbVie Successfully Navigated Top-line Growth Post Humira LOE?
by Sundeep Ganoria
ABBV eyes a 2025 rebound as Skyrizi and Rinvoq drive growth beyond Humira, with oncology and neuroscience adding momentum.
Will BDTX's EGFR Inhibitor Bring a Paradigm Shift in NSCLC Treatment?
by Ekta Bagri
Black Diamond's silevertinib aims to challenge Tagrisso, offering broad EGFR mutation coverage, as key trial results are expected in late 2025.